Association of HLH risk by time-to-HLH (cumulative incidence) for patients undergoing complete HLH workup and mutations or specific T-cell malignancy. (A) Association between HLH risk and mutations of FAS, CASP8. HLA-A, CDKN1B, TP53, TNFA1P3, RARA, and STAT5B. (B) Association between HLH risk and specific T-cell malignancy.